A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis
Status:
NOT_YET_RECRUITING
Trial end date:
2031-09-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, prospective trial designed to evaluate the efficacy and safety of pegylated interferon -2b (Peg-IFN-2b) combined with nucleos(t)ide analogues (NAs) versus NAs monotherapy in patients with compensated hepatitis B cirrhosis. A total of 30 patients with compensated HBV-related cirrhosis will be enrolled and randomized in a 2:1 ratio to either Experimental Group 1 (n=20) or Experimental Group 2 (n=10). The treatment regimens consist of Peg-IFN-2b combined with NAs (ETV/TAF/TMF/TDF) or NAs (ETV/TAF/TMF/TDF) monotherapy.